Tofacitinib for Alopecia Areata
Tofacitinib 5 mg twice daily is an effective off-label treatment for moderate to severe alopecia areata, with approximately 32-49% of patients achieving ≥50% hair regrowth, though it requires continuous therapy to prevent relapse and carries important safety considerations including infection risk, particularly herpes zoster.
Dosing Recommendations
Standard dosing is tofacitinib 5 mg orally twice daily, which has been most extensively studied in alopecia areata 1, 2, 3. This dose balances efficacy with safety, as higher doses (10 mg twice daily) are associated with increased risks of venous thromboembolism and serious infections 4.
- Initial treatment duration: Minimum 3-6 months to assess response 1, 2
- Maintenance therapy: Most patients require ongoing treatment at an average of 7 mg daily to maintain response 1
- Pediatric dosing: 2.5-15 mg daily (typically 5 mg twice daily) has shown acceptable efficacy and safety in children 5, 2
Dose Adjustments
Reduce tofacitinib dose by 50% when coadministered with:
- Strong CYP3A4 inhibitors (e.g., ketoconazole)
- Moderate CYP3A4 inhibitors combined with strong CYP2C19 inhibitors (e.g., fluconazole) 6
Avoid coadministration with strong CYP3A4 inducers (e.g., rifampin) as this reduces tofacitinib exposure and may result in loss of efficacy 6.
Efficacy Expectations
Response varies significantly by disease severity and subtype:
- Moderate AA (SALT 21-49): 33-41% achieve SALT ≤10 5
- Severe AA (SALT 50-94): 30-45% achieve SALT ≤20 5
- Alopecia totalis/universalis: Lower response rates compared to patchy AA 3, 7
- Time to response: Expect 3-9 months for meaningful regrowth 2
Critical caveat: Disease relapse occurs in approximately 54% of patients after discontinuation, typically within 8.5 weeks 3, 7. This necessitates continuous maintenance therapy for sustained benefit.
Predictors of better response include:
- Shorter disease duration
- Peribulbar inflammation on scalp biopsy
- Patchy AA or ophiasis subtypes (vs. totalis/universalis) 3
Pre-Treatment Screening
Before initiating tofacitinib, screen for:
- Tuberculosis: Latent TB testing (IGRA or PPD) is mandatory 8, 4
- Hepatitis B and C: Viral hepatitis screening 8
- Complete blood count: Baseline hemoglobin, lymphocytes, neutrophils 4
- Lipid panel: Baseline cholesterol and triglycerides 4
- Liver function tests: Baseline transaminases 4
- Pregnancy test: In women of childbearing potential 6
Contraindications include:
- Active serious infections
- Current malignancy (except non-melanoma skin cancer or cervical carcinoma in situ) 4
- Pregnancy 6
Monitoring During Treatment
Laboratory Monitoring Schedule
- Weeks 4-8: CBC, liver enzymes, lipids
- Week 12: CBC, liver enzymes, lipids
- Every 3 months thereafter: CBC, liver enzymes, lipids 8, 4
Clinical Monitoring
- Herpes zoster vaccination: Consider vaccination before treatment initiation, particularly in patients >50 years 4
- Skin examinations: Regular monitoring for non-melanoma skin cancer, especially in high-risk populations 4
- VTE risk assessment: Evaluate for risk factors including age >65, obesity, immobilization, prior VTE history, or Cox-2 inhibitor use 4
Safety Considerations
Common Adverse Events (>4% incidence)
- Nasopharyngitis (10-14%)
- Elevated cholesterol (5-9%)
- Headache (3-9%)
- Upper respiratory infections (6-7%)
- Herpes zoster reactivation (1-5%) 6
The herpes zoster risk is dose-dependent with incidence rates 3-4 times higher than placebo 4. This risk is particularly elevated in Asian populations.
Serious Safety Concerns
Venous thromboembolism: The 5 mg twice daily dose carries approximately 3-fold higher PE risk compared to TNF inhibitors (absolute incidence rate 0.3 vs 0.1) 4. Avoid tofacitinib in patients with:
- History of VTE (10-fold increased risk)
- Active Cox-2 inhibitor use (2-fold increased risk)
- Multiple VTE risk factors (age >65, obesity, recent surgery, immobilization) 4
Serious infections: Risk increases with age, particularly in patients >65 years. The EMA has restricted use in this age group 4.
Malignancy: While overall cancer rates are not increased, non-melanoma skin cancer risk may be elevated. Regular dermatologic surveillance is essential 4.
Cytopenias: Monitor for anemia (may worsen due to JAK2 inhibition), neutropenia, and lymphopenia 4.
Contraindicated Combinations
Do not combine tofacitinib with:
- Biologic DMARDs
- Potent immunosuppressants (azathioprine, cyclosporine, tacrolimus)
- Other JAK inhibitors 6
These combinations increase immunosuppression risk without established safety data.
Special Populations
Pregnancy and Lactation
Tofacitinib is not recommended during pregnancy due to fetotoxic and teratogenic effects in animal studies 6. Women of childbearing potential should use effective contraception.
Pediatric Patients
Tofacitinib shows comparable efficacy and tolerability in pediatric AA (ages 2-17 years) at 5 mg twice daily or weight-based equivalent 5, 2. Adverse events are generally limited to grade I-II infections with no serious events reported in short-term studies.
Older Adults
Exercise caution in patients >65 years due to increased infection risk. The EMA has restricted tofacitinib use in this population 4.
Treatment Algorithm
- Confirm diagnosis: Moderate to severe AA (SALT >20) refractory to conventional therapy
- Screen for contraindications: Active infection, malignancy, pregnancy, VTE risk factors
- Complete pre-treatment testing: TB, hepatitis, CBC, lipids, LFTs
- Initiate tofacitinib 5 mg twice daily
- Monitor response at 3 months: Continue if any improvement; consider discontinuation if no response
- Assess full response at 6 months: Determine maintenance strategy
- Continue indefinitely for maintenance: Tapering typically results in relapse within 2 months
- Monitor labs every 3 months: CBC, LFTs, lipids
Key pitfall: Premature discontinuation leads to rapid relapse. Set realistic expectations with patients that this is likely a long-term therapy requirement 3, 7.